PMID- 25435121
OWN - NLM
STAT- MEDLINE
DCOM- 20150129
LR  - 20221109
IS  - 1557-8240 (Electronic)
IS  - 0031-3955 (Linking)
VI  - 62
IP  - 1
DP  - 2015 Feb
TI  - Neuroblastoma: paradigm for precision medicine.
PG  - 225-56
LID - S0031-3955(14)00194-1 [pii]
LID - 10.1016/j.pcl.2014.09.015 [doi]
AB  - Neuroblastoma (NB) is the third most common pediatric cancer. Although NB 
      accounts for 7% of pediatric malignancies, it is responsible for more than 10% of 
      childhood cancer-related mortality. Prognosis and treatment are determined by 
      clinical and biological risk factors. Estimated 5-year survival rates for 
      patients with non-high-risk and high-risk NB are more than 90% and less than 50%, 
      respectively. Recent clinical trials have continued to reduce therapy for 
      patients with non-high-risk NB, including the most favorable subsets who are 
      often followed with observation approaches. In contrast, high-risk patients are 
      treated aggressively with chemotherapy, radiation, surgery, and myeloablative and 
      immunotherapies.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Irwin, Meredith S
AU  - Irwin MS
AD  - Division of Hematology-Oncology, Hospital for Sick Children, University of 
      Toronto, 555 University Ave, Toronto, ON M5G1X8, Canada.
FAU - Park, Julie R
AU  - Park JR
AD  - Division of Hematology-Oncology, Seattle Children's Hospital, University of 
      Washington School of Medicine, Fred Hutchinson Cancer Research Center, 4800 
      Sandpoint Way NE, Seattle, WA 98105, USA. Electronic address: 
      julie.park@seattlechildrens.org.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Pediatr Clin North Am
JT  - Pediatric clinics of North America
JID - 0401126
SB  - IM
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Mutation
MH  - Neoplasm Staging
MH  - Neuroblastoma/genetics/*pathology/therapy
MH  - Prognosis
MH  - Risk Assessment
MH  - Risk Factors
MH  - Survival Rate
OTO - NOTNLM
OT  - ALK (anaplastic lymphoma kinase)
OT  - Immunotherapy
OT  - MYCN
OT  - Myeloablative therapy (MAT)
OT  - Neuroblastoma
OT  - Phox2B
OT  - Risk stratification
OT  - Segmental chromosome aberrations (SCA)
EDAT- 2014/12/02 06:00
MHDA- 2015/01/30 06:00
CRDT- 2014/12/02 06:00
PHST- 2014/12/02 06:00 [entrez]
PHST- 2014/12/02 06:00 [pubmed]
PHST- 2015/01/30 06:00 [medline]
AID - S0031-3955(14)00194-1 [pii]
AID - 10.1016/j.pcl.2014.09.015 [doi]
PST - ppublish
SO  - Pediatr Clin North Am. 2015 Feb;62(1):225-56. doi: 10.1016/j.pcl.2014.09.015.